Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 28, 2026, 16:10Matías J Alet: An Age-Related Etiologic Shift for Young Stroke In Uruguay
-
Feb 28, 2026, 16:03Alia Alghwiri: Patient Education to Improve Quality of Life of Stroke Survivors
-
Feb 28, 2026, 15:46Shreya Agrawal: Integrated Risk Scores for Thrombosis and Bleeding
-
Feb 28, 2026, 15:02Stéphanie Forté: Advancing Stroke Prevention in Adults With Sickle Cell Disease Through Transcranial Doppler
-
Feb 28, 2026, 14:52Jonathan Douxfils: Are All Progestin-Only Contraceptives Truly ‘Neutral’ for VTE Risk?
-
Feb 28, 2026, 14:48WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
-
Feb 28, 2026, 14:43Fabrice Cognasse: Honored to Contribute to New Reference Work on Platelets in Disease
-
Feb 28, 2026, 14:36Shadi Tabibian: Global Trends in Prenatal Diagnosis of Hemophilia A and B Over Two Decades
-
Feb 28, 2026, 14:14Omar Adwan։ ESR in Inflammation and Disease Assessment